
Sacituzumab Tirumotecan Cuts Death Risk by 32% and Disease Progression Risk by 41% in Advanced Endometrial Cancer
Merck’s Sacituzumab Tirumotecan Cuts Risk of Death by 32% in Advanced Endometrial Cancer in Phase 3 TroFuse-005 Trial Merck, known as MSD outside the United States and Canada, has announced…













